Abstract The combination of recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge (ACS) carrier has been shown to induce bone formation in a number of preclinical and clinical investigations. In 2002, rhBMP-
Introduction
Surgeons conducting bone grafting procedures have been searching for a bone graft substitute to avoid harvesting autogenous bone because of its associated complications. The identification and development of recombinant human bone morphogenetic protein-2 (rhBMP-2) has lead to the commercial availability for the first time of an osteoinductive autograft replacement (INFUSE® Bone Graft, Medtronic Spinal and Biologics, Memphis, TN). Prior to this, only osteoconductive ceramic-based materials were commercially available but they have limited clinical utility, since they have to be used in combination with autograft bone to be effective. INFUSE® Bone Graft (Fig. 1) is cleared for use in interbody spine fusion, fresh tibial fractures, and oral maxillofacial bone grafting procedures. rhBMP-2 is the most researched and published bone graft material and is arguably one of the most significant advances in orthopaedics. This review article summarises the clinical findings of rhBMP-2 in spine, orthopaedic and oral maxillofacial applications. All of these studies involved the use of INFUSE® Bone Graft, which contains rhBMP-2 at a concentration of 1.5 mg/cc delivered on an absorbable collagen sponge (ACS) ( Table 1) .
Spinal applications
rhBMP-2 has been studied extensively in preclinical spine fusion models in several species, including non-human primates [13, 14] . These studies consistently showed rhBMP-2 to be equivalent and, in many cases, superior to autogenous bone. In 2002, INFUSE® Bone Graft was approved by the US Food and Drug Administration (FDA) as a replacement for autogenous bone graft in anterior lumbar interbody fusion (ALIF), used in combination with the LT-CAGE® Lumbar Tapered Fusion Device (Medtronic Spinal and Biologics, Memphis, TN). Its approval was based on the results of a prospective, randomised, multicentre clinical trial. The trial involved 279 patients with degenerative disc disease (DDD), randomised to receive either rhBMP-2/ACS or autogenous bone from the iliac crest. Based on computed tomography (CT) evaluation, Burkus et al. [6] reported 2-year fusion rates of 94.5% versus 88.7% for rhBMP-2/ACS and autograft, respectively. There was no statistical difference at any of the followup intervals in Oswestry, back pain and leg pain scores, and neurological status improved in both treatment groups with similar outcomes. In the autograft control group, a 5.9% adverse event rate related to the autograft harvest site occurred and 32% reported graft site discomfort at 2 years. A subsequent integrated analysis by Burkus et al. [7] of two separate ALIF LT-CAGE® clinical studies was performed using an analysis of covariance to adjust for preoperative variables in a total of 679 patients. Of these patients, 277 had their cages implanted with rhBMP-2/ACS and the rest with iliac crest autograft. The patients treated with rhBMP-2/ACS had statistically superior outcomes with regards to length of surgery, blood loss, hospital stay, reoperation rate, median time to return to work, Oswestry Disability Index scores, physical component scores and pain index of the SF-36 (Short Form, 36 questions) scale, and fusion rate at 6, 12 and 24 months (P<0.05).
Burkus et al. [8] also studied rhBMP-2/ACS in ALIF procedures using structural cortical allografts. This study was a prospective, randomised, multi-centre study of 131 patients randomised to receive threaded allograft dowels filled with either rhBMP-2/ACS or autograft bone from the iliac crest. Fusion rates (P<0.001), Oswestry Disability Index scores, SF-36 physical component summary scores and low back and leg pain scores (P<0.05) were significantly better in the rhBMP-2/ACS group.
Spine surgeons began to develop surgical techniques for conducting interbody fusion procedures through posterior lumbar interbody fusion (PLIF) and, later, transforaminal lumbar interbody fusion (TLIF) procedures. Haid et al. [11] reported on a series of 67 patients with single-level DDD treated with cylindrical threaded cages filled with either rhBMP-2/ACS or iliac crest autograft using a PLIF procedure. At 2 years, the rhBMP- Fig. 1 INFUSE® Bone Graft kits and contents. All four kits (small, medium, large and large II) are FDA-approved for the spine and oral maxillofacial applications, while only the large II kit is approved for orthopaedic trauma applications 2/ACS fusion rate was 92.3% versus only 77.8% for the autograft control patients. Significantly more bone was found outside the disc space in the rhBMP-2/ACS-treated patients but it was not correlated to a recurrence or increase in leg pain from the postoperative state. All other clinical outcome parameters were the same between the two groups. Mummaneni et al. [16] reported on their experience with rhBMP-2/ACS using a TLIF procedure. Of the 40 patients enrolled, 19 received iliac-crest-filled interbody cages and 21 received rhBMP-2/ACS-filled cages. For the rhBMP-2/ ACS group, they placed only 1.4 cc of rhBMP-2/ACS in the anterior portion of the prepared disc space before inserting an additional 1.4 cc of rhBMP-2/ACS in the interbody cage. The mean follow-up period was 9 months and only one patient in each group was determined not to be fused. Schwender et al. [19] obtained a 100% fusion rate in a series of 49 patients using a minimally invasive TLIF procedure. Two patients developed radiculopathies postoperatively, one because of graft dislodgement and a second from contralateral neural foraminal stenosis. Both were resolved with reoperations.
Baskin et al. [1] reported on a multi-centre, prospective, randomised cervical fusion clinical study with the COR-NERSTONE SR® allograft ring (Medtronic Spinal and Biologics, Memphis, TN) filled with either rhBMP-2/ACS or iliac crest autograft and an ATLANTIS® anterior cervical plate (Medtronic Spinal and Biologics, Memphis, TN). The study consisted of 33 patients with DDD requiring one-or two-level fusions. In this study, only 0.4 cc of the rhBMP-2/ACS was placed inside each allograft ring to ensure filling without over-packing the sponge. All of the patients evaluated had solid fusions. At 2 years, the rhBMP-2/ACS group had mean improvement superior to that of the autograft control group in neck disability and arm pain scores (P<0.03). No difference in soft tissue swelling was found between the two study groups when matching the rhBMP-2/ACS volume to the small internal volume of the interbody spacer.
More recently, Glassman et al. [10] reported on the use of rhBMP-2/ACS in single-and multi-level posterolateral spine fusions. They reported retrospectively on 91 patients treated with rhBMP-2/ACS combined with a bulking agent to give the ACS sponge some compression resistance. A large INFUSE® kit (8.0 cc) was wrapped around either local autograft bone or a graft extender. Two independent orthopaedic spine surgeons determined the fusion rate to be 93.4% based on CT evaluations. When they compared the fusion rate of just the primary one-level cases to a comparison group of 35 one-level-autograft-treated patients, the fusions rates were 95.8% versus 88.6%, respectively. Singh et al. [20] also used one large INFUSE® kit in combination with iliac crest autograft in posterolateral spine fusions. They reported on a prospective, single-institution, clinical case-matched, radiographic, cohort study of 52 patients. Based on 2-year CT evaluation, 97% of the rhBMP-2/ACS supplemented autograft patients were classified as fused compared to only 77% of the autograft-only control patients (P<0.05). This challenge was addressed through a prospective 86-patient observational study to understand and document the standard of care and outcomes in the surgical management of tibial fractures [17] . The analysis of patients who had open tibia fractures treated with intermedullary (IM) nails revealed that 41% of the patients required a second surgical intervention. Based on the potential for clinical benefit, this treatment group was selected for follow-up studies with rhBMP-2/ACS. The first of these was a pilot study to assess the safety and feasibility of applying rhBMP-2/ACS in open tibial fractures. Fractures healed in 9 of the 12 patients treated with rhBMP-2/ACS without the need for further intervention. This included 8 of 8 patients who received an IM nail for fracture fixation. These data were used to design and support a larger pivotal clinical trial.
The pivotal study was an international investigation performed by a group of surgeons collectively named the BESTT (BMP-2 Evaluation in Surgery for Tibial Trauma) Study Group [2] . A total of 450 patients from 11 countries were enrolled in this prospective, randomised, controlled study. Patients with an open tibia fracture were assigned to one of three treatment groups: (1) standard care (IM nailing with routine soft tissue management), (2) standard care plus 0.75 mg/cc rhBMP-2/ACS or (3) standard care plus 1.5 mg/ cc rhBMP-2/ACS (INFUSE® Bone Graft). The rhBMP-2/ ACS was placed as an onlay over the fracture at the time of definitive wound closure. The primary endpoint measurement was the proportion of patients who required a secondary intervention within 12 months of wound closure. The definition of secondary intervention was conservative with self-dynamisation by screw breakage or recommendation of secondary intervention with or without actual treatment counted as treatment failures.
Outcomes from the pivotal study revealed a dose-dependent decrease in the rate of secondary interventions, with a 44% reduction for patients who received INFUSE® Bone Graft, relative to control patients. Overall, 74% of INFUSE® Bone Graft patients healed without secondary intervention compared to 54% of control patients. Further analyses showed that INFUSE® Bone Graft patients had fewer hardware failures and significantly faster fracture healing than control patients. Finally, in the most severe fracture cases (GustiloAnderson type-III), there was a reduced rate of infection in the INFUSE® treatment group. The data from this study led to EMEA (European Agency for the Evaluation of Medicinal Products) approval of rhBMP-2/ACS in 2002 and FDA approval in 2004 for open tibial fractures stabilised with an IM nail [2] .
In a follow-up to the BESTT study, Swiontkowski et al. [21] combined the results of the BESTT study with results from a previously unpublished study conducted in the US With the demonstrated ability of rhBMP-2/ACS to induce bone formation in preclinical models and prospective randomised clinical investigations of open tibial fractures, there has been interest in applying rhBMP-2/ACS to other orthopaedic trauma applications. Schwartz and Hicks [18] reported on a retrospective analysis of 18 patients with 19 segmental bone defects treated with rhBMP-2/ACS combined with a calcium sulphate or calcium phosphate bone void filler. Bony union occurred in 16 of 19 defects, with the three failures attributed to patient non-compliance in one case and premature resorption of the calcium sulphate in two cases. In a randomised, controlled, prospective clinical investigation, Jones et al. [12] compared rhBMP-2/ACS combined with cancellous allograft to iliac crest autograft in tibial fractures with critical bone loss. The fractures healed in 13 of 15 patients in the rhBMP-2 group and 10 of 15 in the autograft group without any type of secondary intervention. Adverse events consisted of a higher rate of soft-tissue swelling and erythema in the rhBMP-2 group. However, the rhBMP-2 group had less blood loss and avoided complications associated with iliac crest graft harvest while still achieving a high rate of healing.
Oral maxillofacial applications
In March 2007, INFUSE® Bone Graft was approved by the FDA as an alternative to autogenous bone graft for sinus augmentations, and for localised alveolar ridge augmentations for defects associated with extraction sockets. These applications are the third FDA-approved indication for INFUSE® Bone Graft.
Prior to FDA approval, extensive preclinical and clinical research was performed to examine the feasibility, safety and efficacy of using rhBMP-2/ACS for treating common oral maxillofacial defects. Similar to spine and trauma preclinical research, these studies were performed in a number of animal species [4, 22] . This work demonstrated that rhBMP-2/ACS was effective at inducing viable de novo bone formation capable of implant osseointegration and functional loading. After demonstrating feasibility and efficacy in preclinical studies, clinical investigations were performed.
Boyne et al. [3] performed a feasibility sinus floor augmentation study (n = 12) examining 0.43 mg/cc rhBMP-2 concentration on ACS, which was successful at inducing bone formation in a non-human primate segmental defect model. CT evaluations and histology demonstrated a significant change in height and normal bone formation with the use of rhBMP-2/ACS. Boyne et al. [5] followed up this feasibility sinus floor augmentation study with a larger randomised, controlled, rhBMP-2 dosing study for staged maxillary sinus floor augmentation. In this study, patients were treated with either bone graft (n=13), 0.75 mg/cc rhBMP-2/ACS (n=18) or 1.5 mg/cc rhBMP-2/ACS (n=17). The results demonstrated mean bone height changes from a baseline of 11.29 mm, 9.47 mm and 10.16 mm for the bone graft, 0.75 mg/cc and 1.5 mg/cc treatment groups, respectively. Histological bone core biopsies taken at the time of dental implant placement demonstrated normal bone growth and CT scan bone density readings were comparable between all treatment groups following 6 months of functional loading.
After identifying 1.5 mg/cc of rhBMP-2 as the most effective concentration, a randomised, multi-centre, pivotal study was performed examining the safety and efficacy of INFUSE® Bone Graft in sinus floor augmentations [15] . A total of 160 patients were treated with either 1.5 mg/cc rhBMP-2/ACS (n=82) or bone graft (n=78). The bone graft group consisted of autogenous bone alone or in combination with allogeneic bone. The treatment course included the insertion of INFUSE® Bone Graft followed by 4 to 12 months of bone formation, dental implant placement followed by 12 months of osseointegration, and prosthesis placement followed by 12 months of functional loading. CT scans prior to and following implant placement and bone core biopsies for histological analysis were obtained and analysed.
At 6 months post-op, mean changes in the bone height from baseline were 7.83 mm and 9.46 mm for the INFUSE® Bone Graft and bone graft groups, respectively [15] . Histology demonstrated that both groups experienced significant formation of new trabecular bone that was biologically and structurally similar to the host site. After 6 months of functional loading, the INFUSE® Bone Graft resulted in an implant survival rate of 79%, exceeding the study protocol target success rate of 73%. At 12 months of functional loading, the implant success rates for both groups were comparable (P>0.05). Furthermore, no clinically significant adverse events resulted from the use of INFUSE® Bone Graft.
Another large clinical study performed by Fiorellini et al. [9] examined the efficacy of two doses of rhBMP-2/ACS in 80 patients requiring extraction socket augmentation. An empty control and rhBMP-2/ACS at 0.75 mg/cc or 1.5 mg/cc concentrations were examined. The results demonstrated that the 1.5 mg/cc rhBMP-2/ACS treated sites had about two times the amount of bone compared to the empty control group, preserving ridge height and significantly increasing width at 75%, 50% and 25% of the extraction socket length (ESL). In addition, histology on core bone biopsies showed no differences between the rhBMP-2-induced bone and native bone.
Clinical studies in both maxillary sinus floor augmentations and alveolar ridge augmentation demonstrated that rhBMP-2/ACS at 1.5 mg/cc, INFUSE® Bone Graft, induced significant bone formation suitable for implant placement. The bone induced by rhBMP-2/ACS was found to be biologically similar to native bone and is capable of implant osseointegration and supporting the functional loading of dental prostheses.
Conclusions
Following three separate prospective, Level 1 clinical trials, rhBMP-2/ACS is now commercially available for three FDA-approved clinical indications as INFUSE® Bone Graft (Fig. 2) . These trials have demonstrated that rhBMP-2/ACS at a 1.5-mg/cc concentration is equivalent to autogenous bone in both its ability to form de novo bone and as well as clinical outcomes if prepared and used as studied. The tibia fresh fracture and sinus elevation clinical trials both showed the importance of the rhBMP-2 concentration, with the 1.5-mg/cc concentration being more effective than the 0.75-mg/cc concentration. Furthermore, overfilling a contained defect or device with rhBMP-2/ACS can result in unexpected increases in local rhBMP-2 concentration above 1.5 mg/cc and undesired local effects. When used properly, rhBMP-2/ACS can eliminate the need to harvest autogenous bone for grafting procedures, benefiting both the surgeon and patient.
